Near-infrared Photoimmunotherapy (NIR-PIT) on Cholangiocarcinoma Using a Novel Catheter Device with Light Emitting Diodes

Overview

Journal Cancer Sci

Specialty Oncology

Date 2020 Dec 21

PMID 33345417

Citations 14

Authors

Hajime Hirata

Masaki Kuwatani

Kohei Nakajima

Yuki Kodama

Yasuo Yoshikawa

Mikako Ogawa

Naoya Sakamoto

Affiliations

Soon will be listed here.

Abstract

Near-infrared photoimmunotherapy (NIR-PIT) is a novel therapy for cancers that uses NIR light and antibody-photosensitizer (IR700) conjugates. However, it is difficult to deliver NIR light into the bile duct for cholangiocarcinoma (CCA) from the conventional extracorporeal apparatus. Thus, in this study, we developed a dedicated catheter with light emitting diodes (LEDs) that supersedes conventional external irradiation devices; we investigated the therapeutic effect of NIR-PIT for CCA using the novel catheter. The new catheter was designed to be placed in the bile duct and a temperature sensor was attached to the tip of the catheter to avoid thermal burn. An anti-epidermal growth factor receptor (EGFR) antibody, Panitumumab-IR700 conjugate or anti-human epidermal growth factor receptor type 2 (HER2) antibody, Trastuzumab-IR700 conjugate, was used with EGFR- or HER2-expressing cell lines, respectively. The in vitro efficacy of NIR-PIT was confirmed in cultured cells; the capability of the new catheter for NIR-PIT was then tested in a mouse tumor model. NIR-PIT via the developed catheter treated CCA xenografts in mice. NIR-PIT had an effect in Panitumumab-IR700 conjugate- and Trastuzumab-IR700 conjugate-treated CCA cells that depended on the receptor expression level. Tumor growth was significantly suppressed in mice treated with NIR-PIT using the novel catheter compared with controls (P < .01). NIR-PIT was an effective treatment for EGFR- and HER2-expressing CCA cells, and the novel catheter with mounted LEDs was useful for NIR-PIT of CCA.

Citing Articles

Near-infrared photoimmunotherapy: mechanisms, applications, and future perspectives in cancer research.

Allen D, Szoo M, van Bergen T, Seppelin A, Oh J, Saad M Antib Ther. 2025; 8(1):68-85.

PMID: 39958565 PMC: 11826922. DOI: 10.1093/abt/tbaf001.

Evaluation of a Novel Lateral Emitting Laser Fiber for Near-Infrared Photoimmunotherapy.

Suzuki M, Kobayashi H, Hanaoka H Cancers (Basel). 2024; 16(14).

PMID: 39061197 PMC: 11274731. DOI: 10.3390/cancers16142558.

A Photoactive Supramolecular Complex Targeting PD-L1 Reveals a Weak Correlation between Photoactivation Efficiency and Receptor Expression Levels in Non-Small-Cell Lung Cancer Tumor Models.

Delcanale P, Alampi M, Mussini A, Fumarola C, Galetti M, Petronini P Pharmaceutics. 2023; 15(12).

PMID: 38140116 PMC: 10747218. DOI: 10.3390/pharmaceutics15122776.

Promising Highly Targeted Therapies for Cholangiocarcinoma: A Review and Future Perspectives.

Kuwatani M, Sakamoto N Cancers (Basel). 2023; 15(14).

PMID: 37509347 PMC: 10378186. DOI: 10.3390/cancers15143686.

Quickly evolving near-infrared photoimmunotherapy provides multifaceted approach to modern cancer treatment.

Monaco H, Yokomizo S, Choi H, Kashiwagi S View (Beijing). 2023; 3(3).

PMID: 37448778 PMC: 10343942. DOI: 10.1002/VIW.20200110.

References

Okuyama S, Nagaya T, Ogata F, Maruoka Y, Sato K, Nakamura Y . Avoiding thermal injury during near-infrared photoimmunotherapy (NIR-PIT): the importance of NIR light power density. Oncotarget. 2018; 8(68):113194-113201. PMC: 5762583. DOI: 10.18632/oncotarget.20179. View

Mitsunaga M, Nakajima T, Sano K, Choyke P, Kobayashi H . Near-infrared theranostic photoimmunotherapy (PIT): repeated exposure of light enhances the effect of immunoconjugate. Bioconjug Chem. 2012; 23(3):604-9. PMC: 3401044. DOI: 10.1021/bc200648m. View

Nakajima K, Takakura H, Shimizu Y, Ogawa M . Changes in plasma membrane damage inducing cell death after treatment with near-infrared photoimmunotherapy. Cancer Sci. 2018; 109(9):2889-2896. PMC: 6125438. DOI: 10.1111/cas.13713. View

Euhus D, Hudd C, LaRegina M, Johnson F . Tumor measurement in the nude mouse. J Surg Oncol. 1986; 31(4):229-34. DOI: 10.1002/jso.2930310402. View

Mitsunaga M, Ogawa M, Kosaka N, Rosenblum L, Choyke P, Kobayashi H . Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med. 2011; 17(12):1685-91. PMC: 3233641. DOI: 10.1038/nm.2554. View

Nagaya T, Okuyama S, Ogata F, Maruoka Y, Knapp D, Karagiannis S . Near infrared photoimmunotherapy targeting bladder cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody. Oncotarget. 2018; 9(27):19026-19038. PMC: 5922375. DOI: 10.18632/oncotarget.24876. View

Nagaya T, Okuyama S, Ogata F, Maruoka Y, Choyke P, Kobayashi H . Endoscopic near infrared photoimmunotherapy using a fiber optic diffuser for peritoneal dissemination of gastric cancer. Cancer Sci. 2018; 109(6):1902-1908. PMC: 5989863. DOI: 10.1111/cas.13621. View

Pellat A, Vaquero J, Fouassier L . Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology. Hepatology. 2017; 67(2):762-773. DOI: 10.1002/hep.29350. View

Hirata H, Kuwatani M, Nakajima K, Kodama Y, Yoshikawa Y, Ogawa M . Near-infrared photoimmunotherapy (NIR-PIT) on cholangiocarcinoma using a novel catheter device with light emitting diodes. Cancer Sci. 2020; 112(2):828-838. PMC: 7894014. DOI: 10.1111/cas.14780. View

10.

Nagakawa T, Kayahara M, Ikeda S, Futakawa S, Kakita A, Kawarada H . Biliary tract cancer treatment: results from the Biliary Tract Cancer Statistics Registry in Japan. J Hepatobiliary Pancreat Surg. 2003; 9(5):569-75. DOI: 10.1007/s005340200076. View

11.

Ogawa M, Tomita Y, Nakamura Y, Lee M, Lee S, Tomita S . Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity. Oncotarget. 2017; 8(6):10425-10436. PMC: 5354669. DOI: 10.18632/oncotarget.14425. View

12.

Lee J, Diaz R, Cho K, Lim M, Chung J, Kim W . Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy. J Urol. 2013; 190(4):1192-9. DOI: 10.1016/j.juro.2013.04.077. View

13.

Sano K, Nakajima T, Choyke P, Kobayashi H . Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors. ACS Nano. 2012; 7(1):717-24. PMC: 3586604. DOI: 10.1021/nn305011p. View

14.

Kobayashi H, Choyke P . Near-Infrared Photoimmunotherapy of Cancer. Acc Chem Res. 2019; 52(8):2332-2339. PMC: 6704485. DOI: 10.1021/acs.accounts.9b00273. View

15.

Valle J, Wasan H, Palmer D, Cunningham D, Anthoney A, Maraveyas A . Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362(14):1273-81. DOI: 10.1056/NEJMoa0908721. View

16.

Chong D, Zhu A . The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. Oncotarget. 2016; 7(29):46750-46767. PMC: 5216834. DOI: 10.18632/oncotarget.8775. View

17.

Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M . Genomic spectra of biliary tract cancer. Nat Genet. 2015; 47(9):1003-10. DOI: 10.1038/ng.3375. View

18.

Ramanathan R, Belani C, Singh D, Tanaka M, Lenz H, Yen Y . A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009; 64(4):777-83. DOI: 10.1007/s00280-009-0927-7. View

19.

Sato K, Nagaya T, Mitsunaga M, Choyke P, Kobayashi H . Near infrared photoimmunotherapy for lung metastases. Cancer Lett. 2015; 365(1):112-21. PMC: 4508660. DOI: 10.1016/j.canlet.2015.05.018. View

20.

Waseem D, Tushar P . Intrahepatic, perihilar and distal cholangiocarcinoma: Management and outcomes. Ann Hepatol. 2017; 16(1):133-139. PMC: 5630455. DOI: 10.5604/16652681.1226927. View